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eporting potential conﬂicts of In  the  past  5  years,  Dr.  Spahn  has  received  hono-
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is  the  manufacturer  of  the  ﬁbrinogen  used  in  this  study.  How-
ever,  CSL  Behring  had  no  involvement  in  this  study  and  the
ﬁbrinogen  used  in  the  study  was  regularly  purchased  by  the
Tehran  University  of  Medical  Sciences.nterest
omunicando potenciais conﬂitos de interesse
ear  Editor,
t  was  with  surprise  that  I  saw  recently  the  paper  of  Sadeghi
t  al.1 published  in  your  journal  with  me  as  a  co-author.  As
 matter  of  fact,  I  was  involved  in  the  study  design,  data
nalysis  and  writing  of  the  manuscript.  However,  I  was  not
nvolved  in  the  submission  process  of  the  manuscript  to  your
ournal  which  explains  why  my  conﬂict  of  interest  statement
s  lacking  in  the  current  publication.  This  is  highly  unfortu-
ate  since  openly  declaring  all  potential  conﬂicts  of  interest
re  of  prime  importance  to  me.  I  therefore  declare  in  this
etter  all  my  conﬂicts  of  interests.
Dr.  Spahn’s  academic  department  is  receiving  grant
upport  from  the  Swiss  National  Science  Foundation,
erne,  Switzerland  (grant  numbers:  100  014  138545/1,
3CM30 124117,  33CM30  140339  and  406440-131268),  the
inistry  of  Health  (Gesundheitsdirektion)  of  the  Canton  of
urich,  Switzerland  for  Highly  Specialized  Medicine,  the
wiss  Society  of  Anesthesiology  and  Reanimation  (SGAR),
erne,  Switzerland  (no  grant  numbers  attributed),  the
wiss  Foundation  for  Anesthesia  Research,  Zurich,  Switzer-
and  (no  grant  numbers  attributed),  Bundesprogramm
hancengleichheit,  Berne,  Switzerland  (no  grant  numbers
ttributed),  CSL  Behring,  Berne,  Switzerland  (no  grant  num-
ers  attributed),  Vifor  SA,  Villars-sur-Glâne,  Switzerland  (no
rant  numbers  attributed).
Dr.  Spahn  was  the  chairman  of  the  ABC  Faculty  and  is
he  co-chairman  of  the  ABC-Trauma  Faculty,  which  both
re  managed  by  Physicians  World  Europe  GmbH,  Mannheim,
ermany  and  sponsored  by  unrestricted  educational  grants
rom  Novo  Nordisk  Health  Care  AG,  Zurich,  Switzerland,  CSL
ehring  GmbH,  Marburg,  Germany  and  LFB  Biomédicaments,
ourtaboeuf  Cedex,  France.DOI of original article: http://dx.doi.org/10.1016/j.bjane.2013.10.01
ttp://dx.doi.org/10.1016/j.bjane.2014.09.008
104-0014/© 2015 Sociedade Brasileira de Anestesiologia. Published by Earia  or  travel  support  for  consulting  or  lecturing  from
he  following  companies:  Abbott  AG,  Baar,  Switzerland,
MGEN  GmbH,  Munich,  Germany,  AstraZeneca  AG,  Zug,
witzerland,  Bayer  (Schweiz)  AG,  Zürich,  Switzerland,  Bax-
er  AG,  Volketswil,  Switzerland,  Baxter  S.p.A.,  Roma,  Italy,
.  Braun  Melsungen  AG,  Melsungen,  Germany,  Boehringer
ngelheim  (Schweiz)  GmbH,  Basel,  Switzerland,  Bristol-
yers-Squibb,  Rueil-Malmaison  Cedex,  France  and  Baar,
witzerland,  CSL  Behring  GmbH,  Hattersheim  am  Main,
ermany  and  Berne,  Switzerland,Curacyte  AG,  Munich,  Ger-
any,  Ethicon  Biosurgery,  Sommerville,  New  Jersey,  USA,
resenius  SE,  Bad  Homburg  v.d.H.,  Germany,  Galenica  AG,
ern,  Switzerland  (including  Vifor  SA,  Villars-sur-Glâne,
witzerland),GlaxoSmithKline  GmbH  &  Co.  KG,  Hamburg,
ermany,  Janssen-Cilag  AG,  Baar,  Switzerland,  Janssen-
ilag  EMEA,  Beerse,  Belgium,  Merck  Sharp  &  Dohme  AG,
uzern,  Switzerland,  Novo  Nordisk  A/S,  Bagsvärd,  Den-
ark,  Octapharma  AG,  Lachen,  Switzerland,  Organon  AG,
fäfﬁkon/SZ,  Switzerland,  Oxygen  Biotherapeutics,  Costa
esa,  CA,  Photonics  Healthcare  GmbH,  Munich,  Germany,
atiopharm  Arzneimittel  Vertriebs-GmbH,  Vienna,  Austria,
oche  Diagnostics  International  Ltd,  Reinach,  Switzer-
and,  Roche  Pharma  (Schweiz)  AG,  Reinach,  Switzerland,
chering-Plough  International,  Inc.,  Kenilworth,  New  Jer-
ey,  USA,  Tem  International  GmbH,  Munich,  Germany,  Verum
iagnostica  GmbH,  Munich,  Germany,  Vifor  Pharma  Deutsch-
and  GmbH,  Munich,  Germany,  Vifor  Pharma  Österreich
mbH,  Vienna,  Austria,  Vifor  (International)  AG,  St.  Gallen,
witzerland.
The  only  relationship  with  the  research  presented  in  the
aper  of  Sadeghi  et  al.1 may  be  the  fact  that  I  met  the
enior  author  of  the  paper,  Doctor  Ali  Movafegh,  at  a  CSL
ehring  sponsored  educational  event  and  that  CSL  Behring0
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The  author  declares  no  conﬂicts  of  interest.
Reference. Sadeghi M, Atefyekta R, Azimaraghi O, et al. A randomized, dou-
ble blind trial of prophylactic ﬁbrinogen to reduce bleeding in
cardiac surgery. Rev Bras Anestesiol. 2014;64:253--7.
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